Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC42 Combination Therapy for Chronic Hepatitis B
NCT05107778Phase 2Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jan 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of asc42 in Chronic Hepatitis B (CHB), sponsored by Ascletis Pharma Inc.. Started Jan 2022; status: completed.
02
Drugs
asc42
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05107778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05107778.